Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

3.3%

3 terminated/withdrawn out of 92 trials

Success Rate

95.1%

+8.6% vs industry average

Late-Stage Pipeline

14%

13 trials in Phase 3/4

Results Transparency

3%

2 of 58 completed trials have results

Key Signals

9 recruiting2 with results

Enrollment Performance

Analytics

N/A
40(62.5%)
Phase 3
8(12.5%)
Phase 1
5(7.8%)
Phase 4
5(7.8%)
Early Phase 1
3(4.7%)
Phase 2
3(4.7%)
64Total
N/A(40)
Phase 3(8)
Phase 1(5)
Phase 4(5)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (92)

Showing 20 of 92 trials
NCT07567898Not ApplicableNot Yet Recruiting

Effectiveness of Multidisciplinary Protocolised Interventions on IVT Non-adherence Rates

Role: collaborator

NCT07554911Recruiting

Detection and Optimization of Treatment of Severe Cases of Dry Eye Disease

Role: lead

NCT07364929Not ApplicableRecruiting

Altered Non-Visual Photoreception in Patients With Glaucoma: Impacts on Sleep, Alertness, Mood, and Cognition

Role: collaborator

NCT07341724Not ApplicableNot Yet Recruiting

Telemedicine for Evaluating Dry Eye Disease (DED) Using a Mobile Phone-Attached Portable Automatic Ocular Surface Imaging Device (PAOSID): A Patient-Operated Diagnostic and Continuous Ocular Surface Monitoring (COSM) System

Role: lead

NCT07329777Phase 3Recruiting

Atropine in the Treatment of Myopia Study in Malaysia

Role: collaborator

NCT07329712Recruiting

Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy

Role: lead

NCT07260097Recruiting

Choroidal Venous Congestion Following Scleral Buckling - An Imaging Study

Role: lead

NCT07236671Recruiting

Progression Patterns of Choroidal Venous Alterations

Role: lead

NCT07249216Not ApplicableRecruiting

Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting

Role: lead

NCT03941587Not ApplicableCompleted

Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment

Role: lead

NCT03929731Completed

Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)

Role: lead

NCT07176130Active Not Recruiting

Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore

Role: lead

NCT06984549Recruiting

Telemedicine Evaluation of Dry Eye Disease Using a Portable Automatic Ocular Surface Imaging Device (PAOSID)

Role: collaborator

NCT03140358Phase 3Active Not Recruiting

The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)

Role: lead

NCT02943057Phase 4Completed

Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis

Role: lead

NCT03840668Not ApplicableCompleted

Healthy Living Through Personalized Monitoring of Eyelid Care

Role: lead

NCT05319041Early Phase 1Completed

Herbal Medication to Treat Dry Eye in Peri/ Post-menopausal Women

Role: lead

NCT06863675Phase 3Not Yet Recruiting

Highly Aspherical Lenslet (HAL) and Binocular Vision (BV) Disorders [HALT X(T) Study]

Role: lead

NCT06765603Phase 2Not Yet Recruiting

Evaluating the Efficacy of the Combination of Multi-zonal Contact Lens and Atropine for Controlling Myopia Progression

Role: lead

NCT06731582Phase 3Enrolling By Invitation

Nicotinamide Supplementation in Glaucoma

Role: collaborator